Affimed NV (NASDAQ:AFMD) Shares Sold by New Leaf Venture Partners L.L.C.

New Leaf Venture Partners L.L.C. trimmed its holdings in Affimed NV (NASDAQ:AFMD) by 59.3% in the first quarter, HoldingsChannel.com reports. The fund owned 732,774 shares of the biopharmaceutical company’s stock after selling 1,067,226 shares during the period. Affimed accounts for about 0.8% of New Leaf Venture Partners L.L.C.’s portfolio, making the stock its 16th biggest position. New Leaf Venture Partners L.L.C.’s holdings in Affimed were worth $3,078,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Wellington Management Group LLP grew its stake in Affimed by 0.8% in the first quarter. Wellington Management Group LLP now owns 4,730,733 shares of the biopharmaceutical company’s stock valued at $19,869,000 after acquiring an additional 36,690 shares during the period. Millennium Management LLC grew its stake in Affimed by 7.2% in the fourth quarter. Millennium Management LLC now owns 3,121,914 shares of the biopharmaceutical company’s stock valued at $9,709,000 after acquiring an additional 210,884 shares during the period. Stonepine Capital Management LLC acquired a new position in Affimed in the fourth quarter valued at about $2,221,000. Telemetry Investments L.L.C. lifted its holdings in shares of Affimed by 127.9% in the fourth quarter. Telemetry Investments L.L.C. now owns 425,398 shares of the biopharmaceutical company’s stock valued at $1,323,000 after purchasing an additional 238,719 shares in the last quarter. Finally, Prescott Group Capital Management L.L.C. lifted its holdings in shares of Affimed by 16.1% in the fourth quarter. Prescott Group Capital Management L.L.C. now owns 190,680 shares of the biopharmaceutical company’s stock valued at $593,000 after purchasing an additional 26,480 shares in the last quarter. 37.50% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have recently commented on the company. ValuEngine upgraded Affimed from a “hold” rating to a “buy” rating in a report on Wednesday, March 20th. Zacks Investment Research upgraded Affimed from a “hold” rating to a “strong-buy” rating and set a $4.75 price target on the stock in a report on Friday, March 29th. Svb Leerink assumed coverage on Affimed in a report on Thursday, March 28th. They issued an “outperform” rating and a $8.00 price target on the stock. Finally, Leerink Swann assumed coverage on Affimed in a report on Thursday, March 28th. They issued an “outperform” rating and a $4.17 price target on the stock. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $4.99.

Shares of Affimed stock traded down $0.12 during trading on Friday, reaching $3.20. The stock had a trading volume of 12,436 shares, compared to its average volume of 795,575. The firm has a market cap of $207.14 million, a price-to-earnings ratio of -8.47 and a beta of 3.09. Affimed NV has a 52 week low of $1.40 and a 52 week high of $7.35. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.17 and a quick ratio of 3.16.

Affimed (NASDAQ:AFMD) last issued its quarterly earnings results on Wednesday, May 22nd. The biopharmaceutical company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.19. The company had revenue of $12.89 million for the quarter, compared to analyst estimates of $6.77 million. Affimed had a negative return on equity of 23.61% and a negative net margin of 29.04%. On average, equities analysts expect that Affimed NV will post -0.28 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.chaffeybreeze.com/2019/06/14/affimed-nv-nasdaqafmd-shares-sold-by-new-leaf-venture-partners-l-l-c.html.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Featured Article: Different Types of Derivatives

Want to see what other hedge funds are holding AFMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Affimed NV (NASDAQ:AFMD).

Institutional Ownership by Quarter for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.